Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis

Table 2

Subgroup analysis results.

		Random-effects model		Fixed-effects model		Heterogeneity
Analysis		HR (95% CI)		HR (95% CI)			pH
Cancer type
Colorectal cancer	2	2.07 (0.23, 18.82)	0.518	1.81 (0.94, 3.50)	0.076	91.0%	0.001
Lung cancer	2	1.29 (0.96, 1.72)	0.094	1.29 (0.96, 1.72)	0.094	0.0%	0.886
Esophagus cancer	2	1.70 (1.20, 2.40)	0.030	1.70 (1.20, 2.40)	0.003	0.0%	0.715
Others	2	1.86 (1.39, 2.50)	0.001	1.86 (1.39, 2.50)	0.001	0.0%	0.662
Expression position
Tumor cells	6	1.78 (1.19, 2.65)	0.005	1.77 (1.40, 2.22)	0.001	57.7%	0.037
TILs	2	1.44 (1.04, 2.00)	0.027	1.41 (1.09, 1.83)	0.009	30.2%	0.231
Sample size
<100	2	0.92 (0.46, 1.83)	0.817	0.92 (0.47, 1.78)	0.802	6.5%	0.301
≥100	6	1.80 (1.36, 2.39)	0.001	1.67 (1.40, 1.99)	0.001	54.1%	0.054
Method to estimate HR
Multivariate analysis	5	1.49 (1.17, 1.88)	0.001	1.49 (1.24, 1.80)	0.001	31.9%	0.209
Univariate analysis	3	2.57 (1.17, 5.67)	0.019	2.42 (1.54, 3.78)	0.001	61.4%	0.075